Drug Trial Radar · NCT07474961
BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.
Last checked: Nov 20, 2026Latest source record: Mar 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Mar 2027
Primary completion
Dec 2036
Study completion Dec 2036
Sponsor
- Lead sponsor
- Anne Louise Tølbøll SørensenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
BLOOD-dose is a multicentre, adaptive, randomized, multidomain platform trial designed to optimize treatment dosing strategies in adult patients with haematological diseases. The BLOOD-dose core protocol outlines the overall clinical trial design that applies to all included interventions, while domain-specific appendices (DSA) detail the unique characteristics of each domain and specify domain-specific interventions. New domains will be incorporated over time to address distinct dose-optimization research questions across different haematological conditions and interventions.
Conditions
- Waldenstrom Macroglobulinaemia
- Multiple Myeloma
Interventions
teclistamab OR talquetamab OR elranatamab OR linvoseltamabDrug
ElasTEC: A phase 4, open-label, parallel-group, two-arm domain on the BLOOD-dose platform trial to evaluate the non-inferiority, safety, and effectiveness of reduced-frequency bispecific antibody treatments (teclistamab, talquetamab, elranatamab and linvoseltamab) compared with standard-frequency treatment in patients with relapsed/refractory multiple myeloma.
BTK inhibitors (ibrutinib and zanubrutinib)Drug
BELLIS: A phase 4, open-label, parallel-group, two-arm domain to assess the effectiveness and safety of reduced-dose BTK inhibitors (ibrutinib and zanubrutinib) compared to standard-dose in male and female patients with Waldenström´s macroglobulinemia
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survivalTime frame: OS is defined as the time from randomization until the time of death due to any cause, assessed up to 5 years.
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Aalborg University Hospital
Aalborg, Denmark
Aarhus University Hospital
Aarhus, Denmark
Odense University Hospital
Odense, Denmark
Roskilde University Hospital
Roskilde, Denmark
Copenhagen University Hospital - Rigshospitalet
Copenhagen, Greater Copenhagen Area, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.